Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Surovatamig plus rituximab induces high complete response rates in previously untreated follicular lymphoma

Prof Chan Cheah - Sir Charles Gairdner Hospital, Perth, Australia
Surovatamig plus rituximab induces high complete response rates in previously untreated follicular lymphoma ( Prof Chan Cheah - Sir Charles Gairdner Hospital, Perth, Australia )
18 Jun 2026

Romiplostim thrombopoietin receptor agonist rapidly restores platelet counts in acute ITP in 1L treatment during COVID 19

Dr Frederick Chen - Barts Health NHS Trust, London, UK
Romiplostim thrombopoietin receptor agonist rapidly restores platelet counts in acute ITP in 1L treatment during COVID 19 ( Dr Frederick Chen - Barts Health NHS Trust, London, UK )
18 Jun 2026

CLL TIM risk model predicts infection and treatment need in newly diagnosed chronic lymphocytic leukaemia

Prof Carsten Niemann - Rigshospitalet, Copenhagen, Denmark
CLL TIM risk model predicts infection and treatment need in newly diagnosed chronic lymphocytic leukaemia ( Prof Carsten Niemann - Rigshospitalet, Copenhagen, Denmark )
18 Jun 2026

Risk model predicts relapse after frontline blinatumomab in paediatric B-ALL

Prof Anthony Moorman - Newcastle University, Newcastle, UK
Risk model predicts relapse after frontline blinatumomab in paediatric B-ALL ( Prof Anthony Moorman - Newcastle University, Newcastle, UK )
18 Jun 2026

Epcoritamab induces deep and durable responses in chemotherapy-ineligible elderly patients with diffuse large B-cell lymphoma

Prof Umberto Vitolo - Oncological Institute Candiolo, Turin, Italy
Epcoritamab induces deep and durable responses in chemotherapy-ineligible elderly patients with diffuse large B-cell lymphoma ( Prof Umberto Vitolo - Oncological Institute Candiolo, Turin, Italy )
18 Jun 2026

Brentuximab vedotin added to CHEP improves response in CD30+ peripheral T-cell lymphomas

Prof Marek Trněný - Charles University, Prague, Czechia
Brentuximab vedotin added to CHEP improves response in CD30+ peripheral T-cell lymphomas ( Prof Marek Trněný - Charles University, Prague, Czechia )
18 Jun 2026

Blinatumomab replaces intensive chemo in high-risk paediatric ALL, improving survival

Prof Martin Schrappe - Universitätsklinikum Schleswig-Holstein, Kiel, Germany
Blinatumomab replaces intensive chemo in high-risk paediatric ALL, improving survival ( Prof Martin Schrappe - Universitätsklinikum Schleswig-Holstein, Kiel, Germany )
18 Jun 2026

Gabapentin plus tramadol reduces opioid escalation for mucositis pain in head & neck cancer

Dr Minit Shah - Tata Memorial Centre, Mumbai, India
Gabapentin plus tramadol reduces opioid escalation for mucositis pain in head & neck cancer ( Dr Minit Shah - Tata Memorial Centre, Mumbai, India )
17 Jun 2026

Metronomic chemo plus nivolumab (TMC-I) improves survival in R/M head & neck cancer vs platinum chemotherapy

Dr Minit Shah - Tata Memorial Centre, Mumbai, India
Metronomic chemo plus nivolumab (TMC-I) improves survival in R/M head & neck cancer vs platinum chemotherapy ( Dr Minit Shah - Tata Memorial Centre, Mumbai, India )
17 Jun 2026

Early ctDNA clearance linked to improved outcomes in KRAS G12C-mutant colorectal cancer

Dr Filippo Pietrantonio - Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Early ctDNA clearance linked to improved outcomes in KRAS G12C-mutant colorectal cancer ( Dr Filippo Pietrantonio - Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy )
10 Jun 2026

Giredestrant plus palbociclib shows limited benefit in ER-positive, HER2-negative metastatic breast cancer

Dr Mabel Mardones - Rocky Mountain Cancer Centers, Denver, USA
Giredestrant plus palbociclib shows limited benefit in ER-positive, HER2-negative metastatic breast cancer ( Dr Mabel Mardones - Rocky Mountain Cancer Centers, Denver, USA )
10 Jun 2026

Concurrent thoracic radiotherapy plus chemo-ICI shows no overall survival benefit in ES-SCLC

Dr Bjorn Henning Gronberg - Norwegian University of Science and Technology, Trondheim, Norway
Concurrent thoracic radiotherapy plus chemo-ICI shows no overall survival benefit in ES-SCLC ( Dr Bjorn Henning Gronberg - Norwegian University of Science and Technology, Trondheim, Norway )
10 Jun 2026